Brian joined Abingworth in 2018 based in Boston. He has more than 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharmaceutical companies. He currently is on the board of Abingworth portfolio company eFFECTOR. Previously, Brian was a Partner at SR One, the venture capital arm of GlaxoSmithKline (GSK), where he led investments in and was on the boards of Constellation Pharmaceuticals (NASDAQ: CNST), Dicerna Pharmaceuticals (NASDAQ: DRNA), Nimbus Therapeutics, River Vision (acquired by Horizon Pharma), and Translate Bio (NASDAQ: TBIO) amongst other companies.
Prior to SR One, Brian was at Sirtris Pharmaceuticals where he was responsible for corporate development, operations and post-merger integration after the company’s acquisition by GSK. Earlier in his career, Brian held key roles in operations and R&D at Alantos Pharmaceuticals (acquired by Amgen) and at Eisai. Brian holds a PhD in organic chemistry from the University of Michigan and a BS in chemistry from the University of Massachusetts, where he was a Shapiro scholar. He is an inventor on over 25 patents and applications and is the senior author of a number of publications in prominent journals. He currently serves on the Investment Advisory Board for University of Michigan Biomedical Venture Fund, and the Advisory Boards for Michigan Drug Discovery and NYU Medical School’s Therapeutic Alliances.